Seeing Is Believing
Currently out of the existing stock ratings of Jason Zemansky, 20 are a BUY (57.14%), 12 are a HOLD (34.29%), 3 are a SELL (8.57%).
Analyst Jason Zemansky, currently employed at BAML, carries an average stock price target met ratio of 42.24% that have a potential upside of 15.06% achieved within 61 days.
Jason Zemansky’s has documented 69 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on INSM, Insmed at 20-Mar-2025.
Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 3/16/2023. The price target of $1.5 was fulfilled within 6 days with a profit of $0.32 (17.58%) receiving and performance score of 29.3.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$3
$1.79 (147.93%)
$3
6 months 12 days ago
(26-Sep-2024)
0/4 (0%)
$2.42 (417.24%)
Hold
$7
9 months 18 days ago
(20-Jun-2024)
1/3 (33.33%)
$0.45 (6.87%)
57
Sell
$1
$-0.21 (-17.36%)
$1.5
1 years 2 months 21 days ago
(17-Jan-2024)
6/6 (100%)
$-0.02 (-1.96%)
278
Buy
1 years 3 months 20 days ago
(18-Dec-2023)
1/1 (100%)
$32.69 (83.16%)
358
Buy
$9
$7.79 (643.80%)
1 years 10 months 27 days ago
(11-May-2023)
2/4 (50%)
$4.84 (116.35%)
178
Which stock is Jason Zemansky is most bullish on?
Which stock is Jason Zemansky is most reserved on?
What Year was the first public recommendation made by Jason Zemansky?